{"id":"lu-177-psma-617","safety":{"commonSideEffects":[{"rate":null,"effect":"Hematologic toxicity (anemia, thrombocytopenia, leukopenia)"},{"rate":null,"effect":"Xerostomia (dry mouth)"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Kidney toxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lu-177 PSMA-617 consists of lutetium-177, a beta-emitting radioisotope, conjugated to a small molecule ligand that specifically targets PSMA, a cell-surface antigen highly expressed on prostate cancer cells. Once bound to PSMA-expressing tumors, the radioisotope delivers localized radiation that damages cancer cell DNA, leading to cell death. This approach enables targeted radiotherapy with reduced systemic toxicity compared to conventional chemotherapy.","oneSentence":"Lu-177 PSMA-617 is a radioligand that binds to prostate-specific membrane antigen (PSMA) on cancer cells and delivers targeted radiation to kill them.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:19:43.177Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic castration-resistant prostate cancer (mCRPC) with PSMA expression"}]},"trialDetails":[{"nctId":"NCT04663997","phase":"PHASE2","title":"177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2021-08-11","conditions":"Prostate Cancer","enrollment":200},{"nctId":"NCT06526299","phase":"PHASE2","title":"Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease","status":"RECRUITING","sponsor":"University of Washington","startDate":"2025-04-29","conditions":"Metastatic Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":51},{"nctId":"NCT06780670","phase":"PHASE2, PHASE3","title":"Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-02-27","conditions":"Prostate Cancer","enrollment":443},{"nctId":"NCT06798558","phase":"PHASE2","title":"Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy","status":"RECRUITING","sponsor":"Hackensack Meridian Health","startDate":"2025-03-05","conditions":"Prostate Adenocarcinoma","enrollment":54},{"nctId":"NCT04689828","phase":"PHASE3","title":"177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-06-15","conditions":"Prostatic Neoplasms","enrollment":469},{"nctId":"NCT07145177","phase":"PHASE1","title":"177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-03-16","conditions":"Metastatic Prostate Cancer, Prostate Cancer","enrollment":30},{"nctId":"NCT05658003","phase":"PHASE2","title":"A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-05-05","conditions":"Metastatic Castration-Resistant Prostate Cancer (mCRPC)","enrollment":63},{"nctId":"NCT07477756","phase":"","title":"A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-09-04","conditions":"Prostate Cancer","enrollment":1247},{"nctId":"NCT05435495","phase":"","title":"Mechanisms of Resistance to PSMA Radioligand Therapy","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2021-10-21","conditions":"Prostate Cancer","enrollment":125},{"nctId":"NCT05114746","phase":"PHASE2","title":"Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-01-25","conditions":"Prostate Cancer","enrollment":87},{"nctId":"NCT06288113","phase":"PHASE2","title":"Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2024-08-01","conditions":"Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":40},{"nctId":"NCT06388369","phase":"PHASE1, PHASE2","title":"Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate Cancer","status":"TERMINATED","sponsor":"University Hospital, Essen","startDate":"2025-08-25","conditions":"Very High Risk Prostate Carcinoma","enrollment":1},{"nctId":"NCT06379217","phase":"PHASE1","title":"NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-07-29","conditions":"Metastatic Neuroendocrine Prostate Cancer","enrollment":31},{"nctId":"NCT04720157","phase":"PHASE3","title":"An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-06-09","conditions":"Prostatic Neoplasms","enrollment":1145},{"nctId":"NCT06216249","phase":"PHASE2","title":"Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2024-08-01","conditions":"Prostate Carcinoma, Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8","enrollment":90},{"nctId":"NCT06004661","phase":"PHASE2","title":"Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-04-04","conditions":"Metastatic Castration-Resistant Prostate Cancer (mCRPC)","enrollment":20},{"nctId":"NCT07450157","phase":"","title":"A Study of Patient Characteristics, Treatment Patterns and Outcomes Among Patients Treated With 177Lu-PSMA-617","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-06-23","conditions":"Prostate Cancer","enrollment":6448},{"nctId":"NCT05849298","phase":"PHASE2","title":"A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-01-03","conditions":"Prostatic Neoplasm","enrollment":49},{"nctId":"NCT07047118","phase":"PHASE2","title":"A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-07-03","conditions":"Prostatic Cancer, Castration-Resistant","enrollment":130},{"nctId":"NCT04443062","phase":"PHASE2","title":"Lutetium-177-PSMA-617 in Oligo-metastatic Hormone Sensitive Prostate Cancer","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2020-07-20","conditions":"Prostate Cancer","enrollment":58},{"nctId":"NCT06959433","phase":"PHASE3","title":"Lu-177 PSMA Treatment in Cell Renal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Ankara University","startDate":"2026-05-01","conditions":"Metastatic Renal Cancer","enrollment":20},{"nctId":"NCT06964958","phase":"PHASE2","title":"177LuPSMA in Renal Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2025-07-31","conditions":"Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma, Kidney Cancer","enrollment":24},{"nctId":"NCT06855277","phase":"PHASE3","title":"Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-07-01","conditions":"Prostate Cancer","enrollment":940},{"nctId":"NCT06894511","phase":"PHASE2","title":"An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-09-11","conditions":"Metastatic Castration Resistant Prostate Cancer (mCRPC)","enrollment":7},{"nctId":"NCT07226986","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-12-05","conditions":"PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy","enrollment":123},{"nctId":"NCT05670106","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-05-16","conditions":"Metastatic Castration-Resistant Prostate Cancer (mCRPC)","enrollment":62},{"nctId":"NCT06700057","phase":"","title":"Clinical and Dosimetric Study of Patients Treated With 177Lu-PSMA-617 for Prostate Cancer.","status":"RECRUITING","sponsor":"Institut Bergonié","startDate":"2023-11-01","conditions":"Prostate Cancer, Metastasis","enrollment":50},{"nctId":"NCT07219147","phase":"PHASE1","title":"177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-03-05","conditions":"Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":30},{"nctId":"NCT06145633","phase":"PHASE2","title":"Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2024-09-18","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":15},{"nctId":"NCT06866938","phase":"PHASE2","title":"Study of Re-treatment With [177Lu]Lu-PSMA in Men With Metastatic Castration Resistance Prostate Cancer","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2025-04-11","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":58},{"nctId":"NCT06531499","phase":"PHASE1","title":"A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-11-11","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":106},{"nctId":"NCT05766371","phase":"PHASE2","title":"Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2023-12-15","conditions":"Castrate Resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Prostate Cancer","enrollment":48},{"nctId":"NCT07150715","phase":"PHASE2","title":"Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2025-12-12","conditions":"Oligometastatic Prostate Adenocarcinoma, Recurrent Prostate Adenocarcinoma","enrollment":107},{"nctId":"NCT05162573","phase":"PHASE1","title":"EBRT + Lu-PSMA for N1M0 Prostate Cancer","status":"COMPLETED","sponsor":"The Netherlands Cancer Institute","startDate":"2021-12-20","conditions":"Prostatic Neoplasm","enrollment":14},{"nctId":"NCT06568562","phase":"PHASE2","title":"XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"University of Utah","startDate":"2024-12-09","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":32},{"nctId":"NCT07054346","phase":"PHASE1","title":"Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617","status":"RECRUITING","sponsor":"Thomas Hope","startDate":"2025-07-08","conditions":"Prostate Cancer, Prostate Cancer (Diagnosis), High-risk Prostate Cancer","enrollment":45},{"nctId":"NCT06574880","phase":"PHASE1, PHASE2","title":"STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer","status":"RECRUITING","sponsor":"Angela Y. Jia, MD PhD","startDate":"2025-05-13","conditions":"Malignant Neoplasm of Prostate, Locally Advanced Prostate Cancer","enrollment":45},{"nctId":"NCT07025512","phase":"PHASE2","title":"177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-12-03","conditions":"Metastatic Castration Resistant Prostate Cancer, Cytopenia, Anemia","enrollment":40},{"nctId":"NCT06785636","phase":"PHASE1, PHASE2","title":"Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617","status":"RECRUITING","sponsor":"Pathos AI, Inc.","startDate":"2025-02-07","conditions":"mCRPC (Metastatic Castration-resistant Prostate Cancer), Genital Neoplasms, Male, Urogenital Neoplasms","enrollment":252},{"nctId":"NCT05079698","phase":"PHASE1","title":"A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-10-01","conditions":"Prostate Cancer","enrollment":27},{"nctId":"NCT07223034","phase":"PHASE1","title":"A Study of 177Lu-PSMA-617 in People With Gliomas","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-10-27","conditions":"Glioma, Diffuse Astrocytoma, IDH-Wildtype (Grade 2-4), Glioblastoma, IDH-wildtype","enrollment":20},{"nctId":"NCT05613894","phase":"PHASE1","title":"Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"University of Utah","startDate":"2023-07-14","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":33},{"nctId":"NCT06320067","phase":"PHASE3","title":"A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"University College, London","startDate":"2024-06-11","conditions":"Prostate Cancer Metastatic","enrollment":3360},{"nctId":"NCT06852820","phase":"PHASE2","title":"68Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC)","status":"NOT_YET_RECRUITING","sponsor":"Melissa Lumish","startDate":"2025-09-22","conditions":"Liver Cancer, Hepatocellular Carcinoma, Metastatic Liver Cancer","enrollment":10},{"nctId":"NCT05113537","phase":"PHASE1, PHASE2","title":"Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Vadim S Koshkin","startDate":"2022-07-08","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8","enrollment":30},{"nctId":"NCT03042468","phase":"PHASE1, PHASE2","title":"Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2016-12","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT06200103","phase":"PHASE2","title":"Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-05-03","conditions":"Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":236},{"nctId":"NCT06943495","phase":"PHASE1","title":"Personalized vs. Fixed-Activity 177Lu-PSMA-617 Radiopharmaceutical Therapy (PRODIGY-2)","status":"RECRUITING","sponsor":"Jean-Mathieu Beauregard","startDate":"2025-08-15","conditions":"Metastatic Castrate Resistant Prostate Cancer (mCRPC)","enrollment":60},{"nctId":"NCT05633160","phase":"PHASE1, PHASE2","title":"64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT)","status":"TERMINATED","sponsor":"Clarity Pharmaceuticals Ltd","startDate":"2023-06-15","conditions":"Prostatic Neoplasms, Castration-Resistant","enrollment":4},{"nctId":"NCT06738303","phase":"PHASE2","title":"Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer","status":"RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2025-07-14","conditions":"Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer","enrollment":44},{"nctId":"NCT07096999","phase":"","title":"SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy","status":"RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2025-01-23","conditions":"Metastatic Castration-Resistant Prostate Carcinoma","enrollment":60},{"nctId":"NCT05547386","phase":"PHASE3","title":"68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2022-05-09","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":163},{"nctId":"NCT04343885","phase":"PHASE2","title":"In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peter MacCallum Cancer Centre, Australia","startDate":"2020-04-21","conditions":"Metastatic Hormone Naive Prostate Cancer","enrollment":130},{"nctId":"NCT05560659","phase":"PHASE2","title":"Lu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative Radiotherapy","status":"RECRUITING","sponsor":"Peter MacCallum Cancer Centre, Australia","startDate":"2023-12-14","conditions":"Oligometastatic Prostate Cancer","enrollment":92},{"nctId":"NCT06858995","phase":"","title":"Experience of 177Lu-PSMA-617-administration on Port Reservoir (TIVAP)","status":"RECRUITING","sponsor":"Central Hospital, Nancy, France","startDate":"2025-06-05","conditions":"Administration of Therapy","enrollment":107},{"nctId":"NCT06303713","phase":"PHASE1","title":"LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-05-22","conditions":"Prostate Cancer, Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer","enrollment":37},{"nctId":"NCT06972628","phase":"PHASE2","title":"Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617","status":"RECRUITING","sponsor":"Ebrahim S Delpassand","startDate":"2025-05-23","conditions":"Metastatic Castration-Resistant Prostate Cancer, Prostate Cancer Patients With Bone Metastasis, Prostate Cancer (CRPC)","enrollment":30},{"nctId":"NCT03874884","phase":"PHASE1","title":"177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peter MacCallum Cancer Centre, Australia","startDate":"2019-07-09","conditions":"Metastatic Castration Resistant Prostate Cancer (mCRPC)","enrollment":70},{"nctId":"NCT05398302","phase":"PHASE1","title":"Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2024-04-26","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8","enrollment":30},{"nctId":"NCT05803941","phase":"PHASE4","title":"Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-08-14","conditions":"Prostate Cancer","enrollment":700},{"nctId":"NCT05340374","phase":"PHASE1, PHASE2","title":"Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peter MacCallum Cancer Centre, Australia","startDate":"2022-07-14","conditions":"Metastatic Castration-resistant Prostate Cancer, mCRPC","enrollment":35},{"nctId":"NCT05208229","phase":"","title":"The Role of WB-MRI in the Evaluation of Prostate Cancer Patients Treated With Lutetium - Prostate Specific Membrane Antigen (Lu-PSMA)","status":"TERMINATED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2021-02-01","conditions":"Metastatic Castration Resistant Prostate Cancer (mCRPC)","enrollment":2},{"nctId":"NCT04597411","phase":"PHASE1","title":"Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer","status":"RECRUITING","sponsor":"Endocyte","startDate":"2021-04-01","conditions":"Prostatic Neoplasms, Castration-Resistant","enrollment":99},{"nctId":"NCT06389097","phase":"","title":"SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2025-02-03","conditions":"Prostate Cancer, Advanced Cancer","enrollment":80},{"nctId":"NCT06461689","phase":"","title":"Comparison of Changes in Tumor Burden in 68Ga-PSMA-11 PET/CT and 177Lu-PSMA SPECT/CT in Metastatic Castration-resistant Prostate Cancer","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2024-12-31","conditions":"Prostate Cancer Metastatic","enrollment":80},{"nctId":"NCT03805594","phase":"PHASE1","title":"177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2019-05-10","conditions":"Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma","enrollment":43},{"nctId":"NCT06783348","phase":"PHASE2","title":"Radiopharmaceutical Treatment of Advanced Kidney Cancer","status":"NOT_YET_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2025-10-30","conditions":"Metastatic Clear Cell Renal Cell Carcinoma","enrollment":48},{"nctId":"NCT03511664","phase":"PHASE3","title":"Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Endocyte","startDate":"2018-05-29","conditions":"Prostate Cancer","enrollment":861},{"nctId":"NCT03454750","phase":"PHASE2","title":"Radiometabolic Therapy (RMT) With 177Lu PSMA 617 in Advanced Castration Resistant Prostate Cancer (CRPC)","status":"COMPLETED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2022-10-25","conditions":"Metastatic Castration Resistant Prostate Cancer, 68Ga-PSMA PET/CT Positive","enrollment":143},{"nctId":"NCT06496581","phase":"PHASE3","title":"Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2024-09-12","conditions":"Prostate Cancer Metastatic","enrollment":500},{"nctId":"NCT06706921","phase":"PHASE4","title":"18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer","status":"RECRUITING","sponsor":"VA Greater Los Angeles Healthcare System","startDate":"2024-12-15","conditions":"Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Metastatic Prostate Cancer","enrollment":15},{"nctId":"NCT04430192","phase":"PHASE1, PHASE2","title":"Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peter MacCallum Cancer Centre, Australia","startDate":"2020-08-06","conditions":"Prostatic Neoplasms","enrollment":20},{"nctId":"NCT06329830","phase":"PHASE1, PHASE2","title":"177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer","status":"WITHDRAWN","sponsor":"Baptist Health South Florida","startDate":"2024-10","conditions":"Metastatic Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer","enrollment":""},{"nctId":"NCT06546527","phase":"EARLY_PHASE1","title":"Study of [177Lu]Lu-PSMA-137 In Metastatic Castrate Resistant Prostate Cancer（mCRPC）","status":"NOT_YET_RECRUITING","sponsor":"Peking University First Hospital","startDate":"2024-08-01","conditions":"Prostate Cancer","enrollment":12},{"nctId":"NCT04419402","phase":"PHASE2","title":"Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer","status":"UNKNOWN","sponsor":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group","startDate":"2020-08-17","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":162},{"nctId":"NCT05150236","phase":"PHASE2","title":"EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC","status":"UNKNOWN","sponsor":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group","startDate":"2022-04-29","conditions":"Prostatic Neoplasms, Genital Neoplasms, Male, Urogenital Neoplasms","enrollment":93},{"nctId":"NCT06136377","phase":"NA","title":"Evaluation of the Concordance Between Pre-therapy Dosimetry Performed From 68Ga-PSMA-11 Dynamic PET and Post-treatment Dosimetry of 177Lu-PSMA-617 Vectorized Internal Radiotherapy in Patients With Metastatic Prostate Cancer Resistant to Hormonal Castration.","status":"NOT_YET_RECRUITING","sponsor":"Centre Georges Francois Leclerc","startDate":"2024-01-31","conditions":"Patients With Metastatic Castration-resistant Prostate Cancer","enrollment":35},{"nctId":"NCT05613842","phase":"PHASE2","title":"Copper-64 SAR Bombesin in PSMA Negative Prostate Cancer (BOP)","status":"COMPLETED","sponsor":"St Vincent's Hospital, Sydney","startDate":"2022-08-09","conditions":"Prostate Cancer","enrollment":30},{"nctId":"NCT03658447","phase":"PHASE1, PHASE2","title":"PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr)","status":"COMPLETED","sponsor":"Peter MacCallum Cancer Centre, Australia","startDate":"2019-07-12","conditions":"Metastatic Castration Resistant Prostate Cancer","enrollment":37},{"nctId":"NCT04825652","phase":"","title":"177Lu-PSMA-617 Managed Access Program for mCRPC Patients","status":"NO_LONGER_AVAILABLE","sponsor":"Advanced Accelerator Applications","startDate":"","conditions":"Metastatic Castration-resistant Prostate Cancer (mCRPC)","enrollment":""},{"nctId":"NCT03392428","phase":"PHASE2","title":"A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group","startDate":"2018-01-29","conditions":"Cancer of the Prostate, Metastatic Cancer","enrollment":201},{"nctId":"NCT03780075","phase":"PHASE1","title":"Lu177-EB-PSMA617 Radionuclide Treatment in Patients With Metastatic Castration-resistant Prostate Cancer","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2018-04-15","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":50},{"nctId":"NCT05170555","phase":"NA","title":"Diagnosis of Renal Cell Carcinoma on 68Ga-PSMA PET-CT and Radioligand Therapy With 177Lu-EB-PSMA-617","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2021-12-01","conditions":"Renal Cell Carcinoma","enrollment":40},{"nctId":"NCT03545165","phase":"PHASE1, PHASE2","title":"177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2018-04-18","conditions":"Prostate Cancer","enrollment":6},{"nctId":"NCT03042312","phase":"PHASE2","title":"Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy","status":"TERMINATED","sponsor":"Endocyte","startDate":"2017-07-12","conditions":"Metastatic Castration Resistant Prostate Cancer","enrollment":71},{"nctId":"NCT04801264","phase":"EARLY_PHASE1","title":"Diagnosis of Adenoid Cystic Carcinoma on 68Ga-PSMA-617 PET-CT and Therapy With 177Lu-EB-PSMA-617","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2020-09-01","conditions":"Adenoid Cystic Carcinoma","enrollment":40},{"nctId":"NCT03828838","phase":"PHASE1, PHASE2","title":"Lutetium-177-PSMA-617 in Low Volume Metastatic Prostate Cancer","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2018-07-01","conditions":"Prostate Neoplasm","enrollment":10},{"nctId":"NCT03403595","phase":"PHASE1","title":"177Lu-EB-PSMA617 in Patients With Metastatic Castration-resistant Prostate Cancer","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2017-12-01","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":23,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lutetium-177 Prostate Specific Membrane Antigen"],"phase":"phase_3","status":"active","brandName":"Lu-177 PSMA-617","genericName":"Lu-177 PSMA-617","companyName":"Radboud University Medical Center","companyId":"radboud-university-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lu-177 PSMA-617 is a radioligand that binds to prostate-specific membrane antigen (PSMA) on cancer cells and delivers targeted radiation to kill them. Used for Metastatic castration-resistant prostate cancer (mCRPC) with PSMA expression.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}